Advertisement
News
Advertisement

Santaris Pharma A/S and GSK to Develop RNA-Targeted Medicines

Fri, 01/10/2014 - 8:11am

Santaris Pharma A/S has signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines.  Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform to research, develop and commercialize LNA-medicines targeted against up to three targets. Financial details on the deal were not disclosed.

"We are delighted to do this new deal with GSK," said Dr. Henrik Oerum, Chief Scientific Officer and VP business development of Santaris Pharma. "This is the sixth partner deal we have concluded in the past 12 months with pharmaceutical and biotech companies, so it has really been a spectacular year for Santaris Pharma."

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading